Evidence map›Paper›PMID 37492088›Full record

ArticleFrontiers in pharmacology2023

Optimizing the enzymatic release of MMAE from

Marco Zambra, Ivan Ranđelović, Francesco Talarico, Adina Borbély, Laura Svajda, József Tóvári, Gábor Mező, Lizeth Bodero, Sveva Colombo, Federico Arrigoni and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Marco ZambraScience and High Technology Department, University of Insubria, Como, Italy.
Ivan RanđelovićThe National Tumor Biology Laboratory, Department of Experimental Pharmacology, National Institute of Oncology, Budapest, Hungary.
Francesco TalaricoScience and High Technology Department, University of Insubria, Como, Italy.
Adina BorbélyMTA-ELTE Lendület Ion Mobility Mass Spectrometry Research Group and Faculty of Science, Institute of Chemistry, ELTE Eötvös Loránd University, Budapest, Hungary.
Laura SvajdaKINETO Lab Ltd., Budapest, Hungary.
József TóváriThe National Tumor Biology Laboratory, Department of Experimental Pharmacology, National Institute of Oncology, Budapest, Hungary.
Gábor MezőELKH-ELTE Research Group of Peptide Chemistry, Faculty of Science, Eötvös Loránd University, Budapest, Hungary.
Lizeth BoderoScience and High Technology Department, University of Insubria, Como, Italy.
Sveva ColomboScience and High Technology Department, University of Insubria, Como, Italy.
Federico ArrigoniScience and High Technology Department, University of Insubria, Como, Italy.
Elettra FasolaScience and High Technology Department, University of Insubria, Como, Italy.
Silvia GazzolaScience and High Technology Department, University of Insubria, Como, Italy.
Umberto PiarulliScience and High Technology Department, University of Insubria, Como, Italy.
University of Insubria · ITEötvös Loránd University · HUNational Institute of Oncology · HUSemmelweis University · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-Drug Conjugates (ADCs) and Small Molecule-Drug Conjugates (SMDCs) represent successful examples of targeted drug-delivery technologies for overcoming unwanted side effects of conventional chemotherapy in cancer treatment. In both strategies, a cytotoxic payload is connected to the tumor homing moiety through a linker that releases the drug inside or in proximity of the tumor cell, and that represents a key component for the final therapeutic effect of the conjugate. Here, we show that the replacement of the Val-Ala-

Indexed as

cleavable linkerdrug deliverydrug releaseGPLG-linkermonomethyl auristatin Esmall molecule-drug conjugatetumor targeting

Identifiers

PMID37492088
PMCPMC10363981
OpenAlexW4383721044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.